Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

被引:406
作者
Voldborg, BR
Damstrup, L
Spang-Thomsen, M
Poulsen, HS
机构
[1] Univ Hosp, Sect Radiat Biol 5074, Finsen Ctr, Rigshosp, DK-2100 Copenhagen, Denmark
[2] Univ Copenhagen, Inst Mol Pathol, Tumourpathol Lab, Copenhagen, Denmark
关键词
cancer; epidermal growth factor receptor; signalling; tyrosine kinase;
D O I
10.1023/A:1008209720526
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell differentiation and proliferation upon activation through the binding of one of its ligands. The receptor is located at the cell surface, where the binding of a ligand activates a tyrosine kinase in the intracellular region of the receptor. This tyrosine kinase phosphorylates a number of intracellular substrates that activates pathways leading to cell growth, DNA synthesis and the expression of oncogenes such as fos and jun. EGFR is thought to be involved the development of cancer, as the EGFR gene is often amplified, and/or mutated in cancer cells. In this review we will focus on: (I) the structure and function of EGFR, (II) implications of receptor/ligand coexpression and EGFR mutations or overexpression, (III) its effect on cancer cells, (IV) the development of the malignant phenotype and (V) the clinical aspects of therapeutic targeting of EGFR.
引用
收藏
页码:1197 / 1206
页数:10
相关论文
共 101 条
[1]   BINDING OF SH2 DOMAINS OF PHOSPHOLIPASE-C-GAMMA-1, GAP, AND SRC TO ACTIVATED GROWTH-FACTOR RECEPTORS [J].
ANDERSON, D ;
KOCH, CA ;
GREY, L ;
ELLIS, C ;
MORAN, MF ;
PAWSON, T .
SCIENCE, 1990, 250 (4983) :979-982
[2]  
ARTEAGA CL, 1994, CANCER RES, V54, P4703
[3]   Interaction of Heparin-Binding EGF-Like Growth Factor (HB-EGF) with the Epidermal Growth Factor Receptor: Modulation by Heparin, Heparinase, or Synthetic Heparin-Binding HB-EGF Fragments [J].
Besner, Gail E. ;
Whelton, Diane ;
Crissman-Combs, Melissa A. ;
Steffen, Christy L. ;
Kim, Gregory Y. ;
Brigstock, David R. .
GROWTH FACTORS, 1992, 7 (04) :289-296
[4]  
BIGNER SH, 1990, CANCER RES, V50, P8013
[5]   PROTEINS REGULATING RAS AND ITS RELATIVES [J].
BOGUSKI, MS ;
MCCORMICK, F .
NATURE, 1993, 366 (6456) :643-654
[6]   MALIGNANT ASTROCYTOMAS TREATED WITH I-125 LABELED MONOCLONAL-ANTIBODY 425 AGAINST EPIDERMAL GROWTH-FACTOR RECEPTOR - A PHASE II TRIAL [J].
BRADY, LW ;
MIYAMOTO, C ;
WOO, DV ;
RACKOVER, M ;
EMRICH, J ;
BENDER, H ;
DADPARVAR, S ;
STEPLEWSKI, Z ;
KOPROWSKI, H ;
BLACK, P ;
LAZZARO, B ;
NAIR, S ;
MCCORMACK, T ;
NIEVES, J ;
MORABITO, M ;
ESHLEMAN, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (01) :225-230
[7]  
Brunton VG, 1996, ANTI-CANCER DRUG DES, V11, P265
[8]   4,5-DIANILINOPHTHALIMIDE - A PROTEIN-TYROSINE KINASE INHIBITOR WITH SELECTIVITY FOR THE EPIDERMAL GROWTH-FACTOR RECEPTOR SIGNAL-TRANSDUCTION PATHWAY AND POTENT IN-VIVO ANTITUMOR-ACTIVITY [J].
BUCHDUNGER, E ;
TRINKS, U ;
METT, H ;
REGENASS, U ;
MULLER, M ;
MEYER, T ;
MCGLYNN, E ;
PINNA, LA ;
TRAXLER, P ;
LYDON, NB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2334-2338
[9]  
Buchdunger E, 1995, CLIN CANCER RES, V1, P813
[10]  
CARPENTER G, 1990, J BIOL CHEM, V265, P7709